Outcome and determinants of failure to complete primary R‐CHOP treatment for reasons other than non‐response among patients with diffuse large B‐cell lymphoma-Reference-Cited by-同舟云学术

Outcome and determinants of failure to complete primary R‐CHOP treatment for reasons other than non‐response among patients with diffuse large B‐cell lymphoma

Published:2020-04-03 Issue:7 Volume:95 Page:740-748
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Wästerlid Tove¹²^ORCID,Harrysson Sara¹²,Andersson Therese M.‐L.³,Ekberg Sara¹^ORCID,Enblad Gunilla⁴,Andersson Per‐Ola⁵⁶,Jerkeman Mats⁷,Eloranta Sandra¹^ORCID,Smedby Karin E.¹²

Affiliation:

1. Division of Clinical Epidemiology, Department of Medicine SolnaKarolinska Institutet Stockholm Sweden

2. Department of HematologyKarolinska University Hospital Solna Sweden

3. Department of Medical Epidemiology and BiostatisticsKarolinska Institutet Stockholm Sweden

4. Department of OncologyAkademiska University Hospital Uppsala Sweden

5. Department of HematologySouth Älvsborg Hospital Borås Sweden

6. Sahlgrenska AcademyGothenburg University Gothenburg Sweden

7. Department of Oncology and Pathology, Institute of Clinical SciencesLund University Lund Sweden

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25789

Reference27 articles.

1. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

2. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

3. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

4. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

5. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi‐omics integration reveals the oncogenic role of eccDNAs in diffuse large B‐cell lymphoma through STING signalling;Clinical and Translational Medicine;2024-08

2. Multiple Query-based Multi-omics Fusion Algorithm for Cancer Classification and Metastasis Prediction;2024 International Joint Conference on Neural Networks (IJCNN);2024-06-30

3. Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years’ real-world experience in a single institute;Annals of Hematology;2023-04-26

4. Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP(−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group;American Journal of Hematology;2023-01

5. Mediating Effects of Diagnostic Route on the Comorbidity Gap in Survival of Patients with Diffuse Large B-Cell or Follicular Lymphoma in England;Cancers;2022-10-17